Tanshinone II-A: New perspectives for old remedies

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 2, 2013, Pages 149-153

  Xu, Suowen ^a,b   Liu, Peiqing ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer; Combination therapy; Danshen; Tanshinone II A

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AQUAPORIN; ATORVASTATIN; CHEMOKINE; CYTOKINE; DANTONIC; ENZYME; FERULIC ACID; FLUOROURACIL; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ION CHANNEL; MICRORNA; PHOSPHOTRANSFERASE; SCAVENGER RECEPTOR; T 89; TANSHINONE IIA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHINA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INFLAMMATION; INTESTINE ABSORPTION; ISCHEMIC HEART DISEASE; LIVER INJURY; LIVER PROTECTION; LUNG DISEASE; MEDICAL LITERATURE; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PUBLICATION; PULMONARY HYPERTENSION; REVIEW; RHABDOMYOLYSIS; SALVIA MILTIORRHIZA; STABLE ANGINA PECTORIS;

ANIMALS; DITERPENES, ABIETANE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; HUMANS; MOLECULAR TARGETED THERAPY; PLANTS, MEDICINAL; SIGNAL TRANSDUCTION;

EID: 84872694260     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.743995     Document Type: Review

References (34)

1. Gao S, Liu Z, Li H, et al. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 2012;220(1):3-10
2. Zhou L, Zuo Z, Chow MS. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005;45(12):1345-59 (Pubitemid 41643896)
3. Wang J, Lu W, Chen Y, et al. Application of tanshinone IIA or pharmaceutically acceptable salts thereof in preparing medicines for treating or preventing pulmonary hypertension disease. CN102160866; 2011
4. Shang Q, Xu H, Huang L. Tanshinone IIA: A promising natural cardioprotective agent. Evid Based Complement Alternat Med 2012;2012:716459
5. Taehwan K, Myunggyu P. Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity. US8029832; 2011
6. Jia Y, Huang F, Zhang S, et al. Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? A systematic review of randomized controlled trials. Int J Cardiol 2012;157(3):330-40
7. Lee KH, Wang X, Bastow K, et al. Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents. US7795299 B2; 2010
8. Gu L, Liu P, Li G, et al. Tanshinone IIA for prophylaxising or treating atherosclerosis. WO2004058245; 2004
9. Kwak TH, Park MG. Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity. KR20080015495; 2008
10. Tang F, Wu X, Wang T, et al. Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul Pharmacol 2007;46(6):427-38 (Pubitemid 46552282)
11. Tang FT, Cao Y, Wang TQ, et al. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol 2011;650(1):275-84
12. Xu S, Little PJ, Lan T, et al. Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys 2011;515(1-2):72-9
13. Xu S, Liu Z, Huang Y, et al. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-kappaB activation. Transl Res 2012;160(2):114-24
14. Chen W, Tang F, Xie B, et al. Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress. Eur J Pharmacol 2012;674(2-3):359-64
15. Fang J, Xu SW, Wang P, et al. Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. Phytomedicine 2010;18(1):58-64
16. Wang P, Wu X, Bao Y, et al. Tanshinone IIA prevents cardiac remodeling through attenuating NAD(P)H oxidase-derived reactive oxygen species production in hypertensive rats. Pharmazie 2011;66(7):517-24
17. Fu J, Huang H, Liu J, et al. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 2007;568(1-3):213-21 (Pubitemid 46976900)
18. Gao J, Yang G, Pi R, et al. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res 2008;151(2):79-87
19. Xu S, Ogura S, Chen J, et al. LOX-1 in Atherosclerosis: biological Functions and Pharmacological Modifiers. Cell Mol Life Sci 2012; DOI: 10.1007/s00018-012-1194-z 20. Dong Y, Morris-Natschke SL, Lee KH. Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat Prod Rep 2011;28(3):529-42
20. Gong Z, Huang C, Sheng X, et al. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 2009;150(1):104-13
21. Fang ZY, Lin R, Yuan BX, et al. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. Life Sci 2007;81(17-18):1339-45 (Pubitemid 47599531)
22. Chen Y, Wu X, Yu S, et al. Neuroprotection of tanshinone IIA against cerebral ischemia/reperfusion injury through inhibition of macrophage migration inhibitory factor in rats. PLoS One 2012;7(6):e40165
23. Li YS, Wang ZH, Wang J. Effect of tanshinone II A on angiotensin receptor in hypertrophic myocardium of rats with pressure over-loading. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008;28(7):632-6
24. Yu XY, Lin SG, Zhou ZW, et al. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge. Curr Drug Metab 2007;8(4):325-40
25. Zhang W, He H, Liu J, et al. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials 2013;34(1):306-19
26. Tillhon M, Guaman Ortiz LM, Lombardi P, et al. Berberine: new perspectives for old remedies. Biochem Pharmacol 2012;84(10):1260-7
27. Zhu B, Zhai Q, Yu B. Tanshinone IIA protects rat primary hepatocytes against carbon tetrachloride toxicity via inhibiting mitochondria permeability transition. Pharm Biol 2010;48(5):484-7
28. Xu JK, Hiroshi K, Zheng JJ, et al. Protective effect of tanshinones against liver injury in mice loaded with restraint stress. Yao Xue Xue Bao 2006;41(7):631-5 (Pubitemid 44432297)
29. Xu W, Ren X, Tang L, et al. Composition containing tanshinone ingredient and HMG-CoA reductase inhibitor and application thereof. CN101596317; 2008
30. Liu P, Gu L, Xu S. Medicinal composition for preventing and treating atherosclerosis. CN102125567; 2011
31. Chan P, Liu IM, Li YX, et al. Antihypertension induced by tanshinone IIA isolated from the roots of salvia miltiorrhiza. Evid Based Complement Alternat Med 2011;2011:392627
32. Li Y, Yang Y, Yu D, et al. The effect of tanshinone IIA upon the TGF-beta1/Smads signaling pathway in hypertrophic myocardium of hypertensive rats. J Huazhong Univ Sci Technolog Med Sci 2009;29(4):476-80
33. Su CC. Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II. Exp Ther Med 2012;3(3):555-9
34. Wang W, Liu E. Medicinal composition of tanshinone IIA sulfate and ferulic acid and preparation method thereof. CN1806799; 2006.